Portal de Periódicos da CAPES

Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS‐CoV‐2 Infection in Older Adults During the JN.1 Lineage‐Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024

2024; Wiley; Volume: 18; Issue: 11 Linguagem: Inglês

10.1111/irv.70009

1750-2659

Lore Merdrignac, Charlotte Lanièce Delaunay, Nuno Verdasca, Lorena Vega‐Piris, Joan O’Donnell, Noémie Sève, Camino Trobajo‐Sanmartín, Silke Buda, Mariëtte Hooiveld, Ana Paula Rodrigues, Gergő Túri, Neus Latorre‐Margalef, Ivan Mlinarić, Mihaela Lazăr, Marine Maurel, Daniel Castrillejo, Charlene Bennett, Marie‐Anne Rameix‐Welti, Iván Martínez‐Baz, Ralf Dürrwald, Adam Meijer, Aryse Martins Melo, Beatrix Oroszi, Tove Samuelsson Hagey, Sanja Filipović, Frederika Dijkstra, Verónica Gómez, Sabrina Bacci, Marlena Kaczmarek, Esther Kissling,

Viral gastroenteritis research and epidemiology

ABSTRACT We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS‐CoV‐2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage‐predominant period in a European multi‐country test‐negative case–control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12–71), 23% (95% CI: −11–48) and 5% (95% CI: −92–56) among those with symptom onset 1–5, 6–11, and ≥ 12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection.